Your session is about to expire
← Back to Search
Prostacyclin Analogue
Inhaled treprostinil solution for Chronic Obstructive Pulmonary Disease (PERFECT Trial)
Phase 3
Waitlist Available
Research Sponsored by United Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 12
Awards & highlights
Summary
This trial is testing if inhaled treprostinil can help improve exercise ability in people with PH-COPD, as measured by how far they can walk in 6 minutes.
Eligible Conditions
- Chronic Obstructive Pulmonary Disease
- Pulmonary Hypertension
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change From Baseline to Week 12 in 6-Minute Walk Distance (6MWD)
Secondary study objectives
Change From Baseline to Week 12 in 6MWD/Borg Dyspnea Composite Score
Change From Baseline to Week 12 in Borg Dyspnea Score
Change From Baseline to Week 12 in Moderate to Vigorous Physical Activity (MVPA)
+5 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Inhaled TreprostinilExperimental Treatment1 Intervention
Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 micrograms \[mcg\]) 4 times daily (QID)
Group II: PlaceboPlacebo Group1 Intervention
Placebo delivered via an ultrasonic nebulizer for QID administration
Find a Location
Who is running the clinical trial?
United TherapeuticsLead Sponsor
110 Previous Clinical Trials
14,338 Total Patients Enrolled
Medical DirectorStudy DirectorUnited Therapeutics
2,849 Previous Clinical Trials
8,080,692 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger